Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Commonwealth Biotechnologies CBTE - Genomics/DNA Seq

No earlier versions found for this Subject.

Return to Commonwealth Biotechnologies CBTE - Genomics/DNA Seq

Commonwealth Biotechnologies CBTE may be the last of the undiscovered biotechs working in the fields of genomics and dna sequencing.

While other small companies have seen their market caps explode (HYSQ $800M, CRGN $2.7B, GLGC $1.9B etc) as excitment over different gene sciences grow-CBTE is trading near 12 with a tiny market cap of $20M

In additon to dna sequencing cbi-biotech.com
and genomic sequencing cbi-biotech.com
CBTE is also involved in genetic testing services including human genetic analysis and DNA fingerprinting cbi-biotech.com
and protein sequencing cbi-biotech.com

CBTE also does Gene Synthesis-the application of sophisticated technologies to construct completely synthetic “designer genes”
expressing the exact desired protein cbi-biotech.com
and DNA/RNA sequencing cbi-biotech.com

CBTE also offers its proprietary AccuTrac for DNA Sequencing cbi-biotech.com

Hoovers rates CBTE's closest competitors to be Hyseq,Genset and Qiagen
hoovers.com

CBTE float 1.2M, extremely thin, starting to edge up- currently trading near 12 -market cap roughly $20M